Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
US |
|
Alpha Services and Holdings SA
LSE:0RCS
|
GR |
|
F
|
Forte Biosciences Inc
F:37TA
|
US |
|
dotDigital Group PLC
OTC:DOTDF
|
UK |
|
U
|
US Bancorp
F:UB5
|
US |
|
S
|
Stellantis NV
XMUN:8TI
|
NL |
|
A
|
Agricultural Bank of China Ltd
XHAM:EK7
|
CN |
|
D
|
D'Ieteren Group NV
DUS:DJDA
|
BE |
|
C
|
Capital One Financial Corp
F:CFX
|
US |
|
Soditech SA
PAR:ALSEC
|
FR |
|
Swatch Group AG
OTC:SWGAF
|
CH |
|
Avi Ltd
F:IZ6
|
ZA |
|
B
|
Brown-Forman Corp
SWB:BF5B
|
US |
|
Thales SA
PAR:HO
|
FR |
|
M
|
MGIC Investment Corp
BMV:MTG
|
US |
Wall St Price Targets
SUPN Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for SUPN is 64.77 USD with a low forecast of 55.55 USD and a high forecast of 70.35 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SUPN's stock price target?
Price Target
64.77
USD
According to Wall Street analysts, the average 1-year price target for SUPN is 64.77 USD with a low forecast of 55.55 USD and a high forecast of 70.35 USD.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.
